Market Closed -
Nasdaq
04:00:00 2024-05-10 pm EDT
|
5-day change
|
1st Jan Change
|
43.24
USD
|
-5.01%
|
|
-4.78%
|
-28.14%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,735
|
7,175
|
8,357
|
10,938
|
7,866
|
-
|
-
|
Enterprise Value (EV)
1 |
3,233
|
6,446
|
7,855
|
9,959
|
6,938
|
7,031
|
6,660
|
P/E ratio
|
-22
x
|
-34
x
|
-35.7
x
|
-40.9
x
|
-41.3
x
|
-139
x
|
79.9
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
49.4
x
|
79.9
x
|
71.4
x
|
38.4
x
|
13.5
x
|
7.32
x
|
4.8
x
|
EV / Revenue
|
42.7
x
|
71.8
x
|
67.1
x
|
34.9
x
|
11.9
x
|
6.54
x
|
4.07
x
|
EV / EBITDA
|
-14.6
x
|
-17.9
x
|
-17.7
x
|
-25.4
x
|
-21.5
x
|
-108
x
|
32.3
x
|
EV / FCF
|
-12
x
|
-26.6
x
|
-33.1
x
|
-24.1
x
|
-21.8
x
|
-169
x
|
34.3
x
|
FCF Yield
|
-8.31%
|
-3.76%
|
-3.02%
|
-4.15%
|
-4.59%
|
-0.59%
|
2.91%
|
Price to Book
|
26.7
x
|
30.5
x
|
-
|
17.5
x
|
6.2
x
|
5.98
x
|
4.16
x
|
Nbr of stocks (in thousands)
|
132,638
|
153,946
|
167,403
|
181,789
|
181,911
|
-
|
-
|
Reference price
2 |
28.16
|
46.61
|
49.92
|
60.17
|
43.24
|
43.24
|
43.24
|
Announcement Date
|
3/18/21
|
3/18/22
|
3/30/23
|
3/11/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
75.68
|
89.79
|
117
|
285.1
|
581.7
|
1,074
|
1,638
|
EBITDA
1 |
-220.8
|
-360.6
|
-443.2
|
-392.1
|
-323.1
|
-65.22
|
206.2
|
EBIT
1 |
-229.2
|
-373
|
-455.8
|
-412.6
|
-337.3
|
-102.2
|
223
|
Operating Margin
|
-302.87%
|
-415.44%
|
-389.58%
|
-144.69%
|
-57.98%
|
-9.51%
|
13.62%
|
Earnings before Tax (EBT)
1 |
-307.6
|
-386.2
|
-445.7
|
-520.1
|
-318.7
|
-90.9
|
236.1
|
Net income
1 |
-303.5
|
-386.2
|
-446.3
|
-518.3
|
-317.6
|
-92.85
|
211.8
|
Net margin
|
-401.02%
|
-430.12%
|
-381.48%
|
-181.75%
|
-54.6%
|
-8.64%
|
12.93%
|
EPS
2 |
-1.280
|
-1.370
|
-1.400
|
-1.470
|
-1.048
|
-0.3114
|
0.5412
|
Free Cash Flow
1 |
-268.8
|
-242.4
|
-237
|
-413.4
|
-318.3
|
-41.57
|
194.1
|
FCF margin
|
-355.14%
|
-269.92%
|
-202.57%
|
-144.97%
|
-54.71%
|
-3.87%
|
11.85%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
94.12%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
91.67%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/18/21
|
3/18/22
|
3/30/23
|
3/11/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
16.88
|
39
|
40.83
|
11.97
|
36.34
|
73.33
|
96.01
|
79.46
|
141.4
|
122.4
|
131.5
|
177.8
|
178.9
|
EBITDA
1 |
-82.13
|
-114.2
|
-
|
-116.1
|
-
|
-
|
-53.64
|
-
|
-77.42
|
-129.3
|
-110.9
|
-89.75
|
-77.21
|
EBIT
1 |
-86.77
|
-117.5
|
-76
|
-125.5
|
-106.9
|
-104.3
|
-56.82
|
-141
|
-63.14
|
-91.68
|
-101.9
|
-90.93
|
-87.64
|
Operating Margin
|
-513.98%
|
-301.22%
|
-186.16%
|
-1,048.6%
|
-294.09%
|
-142.25%
|
-59.18%
|
-177.43%
|
-44.67%
|
-74.89%
|
-77.48%
|
-51.14%
|
-48.98%
|
Earnings before Tax (EBT)
1 |
-124.8
|
-88.33
|
-41.09
|
-193.1
|
-112
|
-198.8
|
-62.5
|
-146.8
|
-69.69
|
-91.37
|
-98.38
|
-84.5
|
-91.64
|
Net income
1 |
-124.8
|
-88.33
|
-41.09
|
-193.2
|
-112.1
|
-199.1
|
-62.21
|
-144.8
|
-69.44
|
-91.16
|
-97.99
|
-83.71
|
-91.79
|
Net margin
|
-738.96%
|
-226.53%
|
-100.64%
|
-1,614.13%
|
-308.51%
|
-271.55%
|
-64.79%
|
-182.24%
|
-49.12%
|
-74.47%
|
-74.52%
|
-47.08%
|
-51.3%
|
EPS
2 |
-0.4300
|
-0.3000
|
-0.1300
|
-0.6200
|
-0.3400
|
-0.5700
|
-0.1700
|
-0.4000
|
-0.1791
|
-0.2805
|
-0.2926
|
-0.2364
|
-0.2475
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/16/21
|
3/18/22
|
6/1/22
|
2/17/23
|
5/18/23
|
8/15/23
|
11/20/23
|
3/11/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
502
|
729
|
501
|
979
|
928
|
835
|
1,206
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-269
|
-242
|
-237
|
-413
|
-318
|
-41.6
|
194
|
ROE (net income / shareholders' equity)
|
-284%
|
-103%
|
-59.1%
|
-51.9%
|
-33.3%
|
-5.72%
|
14%
|
ROA (Net income/ Total Assets)
|
-44.3%
|
-42%
|
-36.4%
|
-32.6%
|
-27.3%
|
-3.18%
|
11.1%
|
Assets
1 |
684.9
|
919.7
|
1,225
|
1,590
|
1,162
|
2,924
|
1,900
|
Book Value Per Share
2 |
1.050
|
1.530
|
-
|
3.440
|
6.980
|
7.230
|
10.40
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
45.7
|
43.9
|
35.7
|
20.1
|
42.2
|
42.3
|
36.1
|
Capex / Sales
|
60.45%
|
48.9%
|
30.54%
|
7.04%
|
7.25%
|
3.93%
|
2.2%
|
Announcement Date
|
3/18/21
|
3/18/22
|
3/30/23
|
3/11/24
|
-
|
-
|
-
|
Last Close Price
43.24
USD Average target price
86.28
USD Spread / Average Target +99.55% Consensus |
1st Jan change
|
Capi.
|
---|
| -28.14% | 7.87B | | +3.91% | 109B | | +10.87% | 105B | | +1.28% | 22.25B | | -13.14% | 22.09B | | -7.05% | 18.68B | | -38.36% | 17.58B | | -10.66% | 16.85B | | +3.75% | 13.76B | | +36.70% | 12.46B |
Bio Therapeutic Drugs
|